# EDGAR Filing Document

**Accession Number:** 0001837607
**File Stem:** 0001104659-26-014404
**Filing Date:** 2026-2
**Character Count:** 2510
**Document Hash:** e58c4c3da44adb9c8253e149e3225171
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-014404.hdr.sgml**: 20260528

**ACCESSION NUMBER**: 0001104659-26-014404

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260212

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AEON Biopharma, Inc.
- **CENTRAL INDEX KEY:** 0001837607
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 853940478
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 5 PARK PLAZA
- **STREET 2:** SUITE 1750
- **CITY:** IRVINE
- **STATE:** CA
- **ZIP:** 92614
- **BUSINESS PHONE:** (949) 354-6499

**MAIL ADDRESS:**
- **STREET 1:** 5 PARK PLAZA
- **STREET 2:** SUITE 1750
- **CITY:** IRVINE
- **STATE:** CA
- **ZIP:** 92614

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Priveterra Acquisition Corp.
- **DATE OF NAME CHANGE:** 20201222

February 12, 2026

**<u>VIA EDGAR</u>**

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549-6010

**Re: AEON Biopharma, Inc.<br> Registration Statement on Form S-3 (Registration No. 333-293309)**

**Request for Acceleration of Effective Date**

To the addressee set forth above:

In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration by the Securities and Exchange Commission (the "***Commission***") of the effective date of the above-referenced Registration Statement on Form S-3 (Registratiom No. 333-293309) (the "***Registration Statement***") of AEON Biopharma, Inc. We respectfully request that the Registration Statement become effective as of 5:30 p.m., Washington, D.C. time, on February 17, 2026, or as soon as practicable thereafter.

The Company requests that we be notified of such effectiveness by a telephone call to Drew Capurro of Latham & Watkins LLP at (714) 755-8008 that such effectiveness also be confirmed in writing.

---

| | | |
|:---|:---|:---|
| Sincerely, | Sincerely, | Sincerely, |
| **AEON Biopharma, Inc.** | **AEON Biopharma, Inc.** | **AEON Biopharma, Inc.** |
| By: | /s/ Alex Wilson | /s/ Alex Wilson |
|  | Name: | Alex Wilson |
|  | Title: | Chief Legal & Strategy Officer |

---

---

| | |
|:---|:---|
| cc: | <u>Via Email</u> |
|  | Robert Bancroft, AEON Biopharma, Inc. |
|  | Drew Capurro, Esq., Latham & Watkins LLP |

---